Literature DB >> 30637037

Association between 18F-FDG PET/CT and MRI appearance of spinal leptomeningeal disease before and after treatment at a tertiary referral center.

Harry Papasozomenos1, Nandita Guha-Thakurta2, Rory R Mayer3, Jeffrey S Weinberg4, Morris D Groves5, J Matthew Debnam2.   

Abstract

OBJECTIVE: Leptomeningeal disease (LMD), the presence of metastasis in the subarachnoid space, has devastating implications if left untreated. The gold standard for LMD diagnosis is cytologic analysis of cerebrospinal fluid (CSF); MRI is also used to evaluate suspected LMD. The purpose of this study was to compare the appearance of LMD in the spinal canal on 18F-FDG PET/CT imaging with the appearance of LMD on MRI and with CSF cytology.
METHODS: In twenty-one patients with cytologically-proven spinal LMD, findings on 18F-FDG PET/CT, MRI, and CSF cytology at diagnosis of LMD and after the initiation of treatment for LMD were retrospectively reviewed.
RESULTS: At diagnosis of LMD, abnormal 18F-FDG avidity was demonstrated in the spinal canal in six patients, and the anatomic distribution of 18F-FDG activity corresponded to the sites of LMD on MRI. All six of these patients were then treated with intrathecal chemotherapy. Follow-up 18F-FDG PET/CT and MRI were obtained in four of the six cases. In all four cases, normalization of 18F-FDG activity in the spinal canal and reduction of enhancement on MRI corresponded to the cytologic response to treatment, as determined by CSF analysis.
CONCLUSION: 18F-FDG avidity in the spinal canal greater than the normal contents of the canal can suggest spinal LMD. This abnormal avidity may be detected before the diagnosis of LMD has been established with MRI or CSF cytology. The spinal canal should be routinely evaluated on 18F-FDG PET/CT in patients with suspected LMD so that appropriate treatment is initiated.

Entities:  

Keywords:  Mapping categories of interest; Personalization; Recommendation of event attendance

Year:  2015        PMID: 30637037      PMCID: PMC6329473          DOI: 10.5430/jst.v6n1p1

Source DB:  PubMed          Journal:  J Solid Tumors        ISSN: 1925-4067


  25 in total

1.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.

Authors:  C S Straathof; H G de Bruin; D W Dippel; C J Vecht
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

2.  Neurological picture. FDG-PET in meningeal lymphomatosis.

Authors:  Miho Shinohara; Saori Kosaka; Terue Okamura; Toru Yamamoto
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

3.  Demonstration of diffuse leptomeningeal metastasis in a treated case of medulloblastoma with F-18 FDG PET/CT.

Authors:  Madhavi Tripathi; Nikunj Jain; Abhinav Jaimini; Gunjan Garg; Maria M D'souza; Rajnish Sharma; Rajesh K Grover; Anupam Mondal
Journal:  Clin Nucl Med       Date:  2009-08       Impact factor: 7.794

Review 4.  Leptomeningeal carcinomatosis.

Authors:  S A Grossman; M J Krabak
Journal:  Cancer Treat Rev       Date:  1999-04       Impact factor: 12.111

5.  Imaging features of leptomeningeal metastases.

Authors:  D A Collie; J P Brush; G A Lammie; R Grant; I Kunkler; R Leonard; A Gregor; R J Sellar
Journal:  Clin Radiol       Date:  1999-11       Impact factor: 2.350

6.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

Authors:  Heiko Schöder; Ariela Noy; Mithat Gönen; Lijun Weng; David Green; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

7.  Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG positron emission tomography.

Authors:  T Komori; D Delbeke
Journal:  Clin Nucl Med       Date:  2001-11       Impact factor: 7.794

Review 8.  Leptomeningeal metastasis.

Authors:  Marc C Chamberlain
Journal:  Curr Opin Neurol       Date:  2009-12       Impact factor: 5.710

Review 9.  Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.

Authors:  Einat Even-Sapir; Genady Lievshitz; Chava Perry; Yair Herishanu; Hedva Lerman; Ur Metser
Journal:  Radiol Clin North Am       Date:  2007-07       Impact factor: 2.303

10.  18F-FDG uptakes in leptomeningeal metastases from carcinoma of the breast on a positron emission tomography/computerized tomography study.

Authors:  S Shah; V Rangarajan; N Purandare; K Luthra; S Medhi
Journal:  Indian J Cancer       Date:  2007 Jul-Sep       Impact factor: 1.224

View more
  1 in total

Review 1.  [18F]FDG-PET Evaluation of Spinal Pathology in Patients in Oncology: Pearls and Pitfalls for the Neuroradiologist.

Authors:  P Y Patel; I Dalal; B Griffith
Journal:  AJNR Am J Neuroradiol       Date:  2021-10-28       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.